SCHEMBL31269078

SCHEMBL31269078

COc1ccc(Cl)cc1Cn1c(-c2cccc(CCCC(=O)O)c2Cl)nc2c(OC3(C)CC3)ncnc21

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CD274 Q9NZQ7 4/20 0.35
▸ PDCD1 Q15116 3/20 0.35
▸ PTGER1 P34995 8/20 0.34
▸ FFAR4 Q5NUL3 1/20 0.33
▸ PIK3CD O00329 1/20 0.33
▸ ADORA3 P0DMS8 2/20 0.33
▸ PTGDR2 Q9Y5Y4 1/20 0.33
▸ PDCD1LG2 Q9BQ51 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ CTSA P10619 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ CNR2 P34972 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31268895 0.96 PDCD1 (0.36) CD274PDCD1PTGER1FFAR4PIK3CD
SCHEMBL31269428 0.91 PDCD1 (0.34) CD274PDCD1PTGER1PIK3CDADORA3
SCHEMBL30983441 0.90 PDCD1 (0.36) CD274PDCD1PTGER1PIK3CDPTGDR2
SCHEMBL30983843 0.86 PDCD1 (0.36) CD274PDCD1PIK3CDADORA3TSHR
SCHEMBL31269249 0.86 PDCD1 (0.34) CD274PDCD1PTGER1PIK3CDADORA3
SCHEMBL31269222 0.85 CD274 (0.35) CD274PDCD1PTGER1PIK3CDADORA3
SCHEMBL30983814 0.85 PDCD1 (0.34) CD274PDCD1PIK3CDADORA3USP2
SCHEMBL30983813 0.85 PDCD1 (0.34) CD274PDCD1PIK3CDADORA3USP2
SCHEMBL30983431 0.84 PDCD1 (0.34) CD274PDCD1PTGER1PIK3CDCTSA
SCHEMBL30984001 0.84 ADORA3 (0.35) CD274PDCD1PIK3CDADORA3USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback